U.S. starts trial on potential universal flu vaccine

LOS ANGELES, June 28 (Xinhua) -- The Phase 1 clinical trial of a novel influenza vaccine has begun inoculating healthy adult volunteers at the U.S. National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland, the NIH announced on Tuesday.

The placebo-controlled trial will test the safety of a candidate vaccine, BPL-1357, and its ability to prompt immune responses, according to the NIH.

The vaccine candidate was developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID). The trial can enroll up to 100 people aged 18 to 55 years.

"Influenza vaccines that can provide long-lasting protection against a wide range of seasonal influenza viruses as well as those with pandemic potential would be invaluable public health tools," said NIAID Director Anthony S. Fauci.

"The BPL-1357 candidate influenza vaccine being tested in this clinical trial performed very well in pre-clinical studies and we look forward to learning how it performs in people," Fauci said.

Article type: free
User access status:
Subscribe now to our Premium Plan for an ad-free and unlimited reading experience!

Next In World

Twitter breach exposed anonymous account owners
Chad and rebels sign peace deal
Fourth person reported drowned in New Mexico wildfire area floods
Demand for grocery delivery cools as food costs rise
Climate change puts Lyme disease in focus for France's Valneva after COVID blow
Explainer-What is at stake for investors in Kenya's elections?
Two more grain ships sail from Ukraine as third port opens
GoFundMe scammer who used story of homeless US veteran gets five years
Dutch man accused in online harassment case found guilty
Shadow profiles from US therapist directory spark�startup backlash

Others Also Read